Ionis Pharmaceuticals

Youtube Subscribe

Open: 44.59 Close: 45.63 Change: 1.04

Can you guess what an AI found about Ionis Pharmaceuticals.

This document will help you to evaluate Ionis Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ionis Pharmaceuticals are: Pharmaceuticals, Ionis, share, NASDAQIONS, formerly, Isis, focus, …

Concept Map

Semantic Network

Stock Summary

SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin am.

Today's Summary

Ionis Pharmaceuticals (Ionis), formerly Isis Pharmaceuticals, focuses on the discovery and development of RNA-targeted drugs. Morgan Stanley upped their target price on shares of IONS Pharmaceuticals from $42.00 to $45.00. Biogen announced additional data from a Phase 1b trial.

Today's News

Ionis Pharmaceuticals (Ionis), formerly Isis Pharmaceuticals, focuses on the discovery and development of RNA-targeted drugs. GlobalData tracks drug-specific phase transition and likelihood of approval scores. Biogen announced additional data from a Phase 1b trial. Raymond James & Associates lessened its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - defense world.com. Morgan Stanley upped their target price on shares of IONS Pharmaceuticals from $42.00 to $45.00. Ionis Pharmaceuticals stock (nasdaq:ions), quotes and news summary - benzinga.com. Complete the form below to receive the latest headlines and analysts recommendations. Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings results on August 9th.

Stock Profile

"Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California."

Keywords

How much time have you spent trying to decide whether investing in Ionis Pharmaceuticals? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ionis Pharmaceuticals are: Pharmaceuticals, Ionis, share, NASDAQIONS, formerly, Isis, focus, and the most common words in the summary are: excipient, pharmaceutical, phase, ionis, sodium, stock, polysorbate, . One of the sentences in the summary was: Morgan Stanley upped their target price on shares of IONS Pharmaceuticals from $42.00 to $45.00. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #excipient #pharmaceutical #phase #ionis #sodium #stock #polysorbate.

Read more →

Youtube Subscribe

---